Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AMPE | Ampio Pharmaceuticals, Inc.

Index	-	P/E	-	EPS (ttm)	-118.32	Insider Own	-	Shs Outstand	0.76M	Perf Week	-1.44%
Market Cap	3.10M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	0.69M	Perf Month	2.75%
Income	-14.00M	PEG	-	EPS next Q	-	Inst Own	13.10%	Short Float / Ratio	3.09% / 0.67	Perf Quarter	-12.70%
Sales	-	P/S	-	EPS this Y	15.70%	Inst Trans	-	Short Interest	0.02M	Perf Half Y	-20.50%
Book/sh	8.69	P/B	0.47	EPS next Y	-	ROA	-106.90%	Target Price	-	Perf Year	-82.88%
Cash/sh	9.27	P/C	0.44	EPS next 5Y	-	ROE	-139.50%	52W Range	3.35 - 26.10	Perf YTD	-8.75%
Dividend	-	P/FCF	-	EPS past 5Y	38.10%	ROI	-	52W High	-84.25%	Beta	1.75
Dividend %	-	Quick Ratio	3.70	Sales past 5Y	-	Gross Margin	-	52W Low	22.54%	ATR	0.51
Employees	5	Current Ratio	3.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	47.75	Volatility	12.01% 12.32%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	33.90%	Profit Margin	-	Rel Volume	0.41	Prev Close	4.12
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	31.59K	Price	4.11
Recom	3.00	SMA20	0.30%	SMA50	-5.50%	SMA200	-17.95%	Volume	13,073	Change	-0.25%

Aug-31-23 06:30AM	Ampio Pharmaceuticals Announces Reverse Stock Split (PR Newswire) +10.86%
May-26-23 04:40PM	Ampio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common Stock (PR Newswire)
Apr-18-23 06:30AM	AMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERS (PR Newswire) +22.19%
Jan-17-23 08:20AM	AMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERS (PR Newswire) -7.28%
Dec-27-22 05:44PM	Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards (PR Newswire) -6.21%
04:53PM	Loading…
Nov-17-22 04:53PM	Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension (PR Newswire) +12.62%
Nov-08-22 04:30PM	Ampio Pharmaceuticals Announces Fifteen-to-One Reverse Stock Split (PR Newswire) -26.14%
Oct-14-22 04:01PM	Ampio Pharmaceuticals Issues Letter to Stockholders (PR Newswire) -7.84%
Oct-04-22 08:50AM	Ampio Pharmaceuticals Announces NYSE American Has Commenced Delisting Proceedings (PR Newswire) -64.90%
Jul-24-22 08:41AM	6 Penny Stocks With 1,000% Upside Potential (InvestorPlace)
Jun-02-22 04:30PM	Ampio Pharmaceuticals' CEO Mike Martino Issues Letter to Stockholders (PR Newswire) +7.22%
May-17-22 11:34AM	Ampio's Independent Committee Launches Investigation Related To AP-013 Trial (Benzinga)
May-16-22 04:10PM	Ampio Pharmaceuticals Reports First-Quarter Financial Results (PR Newswire) -6.74%
04:05PM	Ampio Independent Committee to Conduct Investigation (PR Newswire)
Apr-27-22 04:45PM	Ampio Pharmaceuticals, Inc. to Hold Conference Call (PR Newswire)
05:49PM	Loading…
Apr-20-22 05:49PM	AMPIO PROVIDES REGULATORY UPDATE (PR Newswire) -5.05%

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis-related pain. It focuses on the preclinical development of AR-300, a novel proprietary, small molecule formulation for the treatment of osteoarthritis of the knee. The company is headquartered in Englewood, Colorado.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BUCHI J KEVIN	Director	Jun 09	Buy	0.29	21,858	6,284	146,858	Jun 13 12:07 PM
BUCHI J KEVIN	Director	Jun 08	Buy	0.30	25,000	7,400	125,000	Jun 09 02:26 PM
MARTINO MICHAEL A	CEO	May 24	Buy	0.29	76,890	22,121	76,890	May 26 01:30 PM
BUCHI J KEVIN	Director	May 16	Buy	0.27	32,534	8,924	100,000	May 17 04:25 PM
BUCHI J KEVIN	Director	May 15	Buy	0.25	44,026	10,857	67,466	May 16 03:30 PM
Stevens David R	Director	May 12	Buy	0.22	45,000	9,900	103,971	May 12 05:26 PM
BUCHI J KEVIN	Director	May 12	Buy	0.24	23,440	5,513	23,440	May 16 03:30 PM
Stevens David R	Director	May 11	Buy	0.22	50,000	10,875	58,971	May 12 05:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMPE | Ampio Pharmaceuticals, Inc.

Upgrade your FINVIZ experience